Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.

Bødker JS, Severinsen MT, El-Galaly TC, Brøndum RF, Laursen MB, Falgreen S, Nyegaard M, Schmitz A, Jakobsen LH, Schönherz AA, Due H, Reinholdt L, Bøgsted M, Dybkær K, Johnsen HE.

Exp Hematol Oncol. 2017 Jan 11;6:3. doi: 10.1186/s40164-016-0063-0. eCollection 2017.

2.

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.

Falgreen S, Ellern Bilgrau A, Brøndum RF, Hjort Jakobsen L, Have J, Lindblad Nielsen K, El-Galaly TC, Bødker JS, Schmitz A, H Young K, Johnsen HE, Dybkær K, Bøgsted M.

PLoS One. 2016 Oct 4;11(10):e0163711. doi: 10.1371/journal.pone.0163711. eCollection 2016.

3.

Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.

Green TM, Jensen AK, Holst R, Falgreen S, Bøgsted M, de Stricker K, Plesner T, Mourits-Andersen T, Frederiksen M, Johnsen HE, Pedersen LM, Møller MB.

Br J Haematol. 2016 Sep;174(6):876-86. doi: 10.1111/bjh.14138. Epub 2016 May 16.

PMID:
27196819
4.

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.

Bilgrau AE, Falgreen S, Petersen A, Kjeldsen MK, Bødker JS, Johnsen HE, Dybkær K, Bøgsted M.

BMC Bioinformatics. 2016 Apr 11;17:159. doi: 10.1186/s12859-016-0997-6.

5.

Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review.

Østergaard Poulsen M, Krogh Jørgensen L, Sørensen S, Falgreen S, Støve Bødker JS, Bach Laursen M, Schmitz A, Johnsen HE, Dybkær K, Bøgsted M.

Dan Med J. 2016 Mar;63(3). pii: A5206. Review.

PMID:
26931194
6.

High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.

Marques SC, Ranjbar B, Laursen MB, Falgreen S, Bilgrau AE, Bødker JS, Jørgensen LK, Primo MN, Schmitz A, Ettrup MS, Johnsen HE, Bøgsted M, Mikkelsen JG, Dybkær K.

Exp Hematol. 2016 Apr;44(4):238-46.e2. doi: 10.1016/j.exphem.2015.12.007. Epub 2016 Feb 17.

PMID:
26854484
7.

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.

Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M.

BMC Cancer. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6.

8.

Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.

Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE.

J Clin Oncol. 2015 Apr 20;33(12):1379-88. doi: 10.1200/JCO.2014.57.7080. Epub 2015 Mar 23.

9.

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies.

Marques SC, Laursen MB, Bødker JS, Kjeldsen MK, Falgreen S, Schmitz A, Bøgsted M, Johnsen HE, Dybkaer K.

Oncotarget. 2015 Jan 1;6(1):7-25. Review.

10.

Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.

Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, Tramm AM, Baech J, Jacobsen CL, Gaihede M, Kjeldsen MK, Bødker JS, Dybkaer K, Bøgsted M, Johnsen HE.

Cytometry B Clin Cytom. 2015 Jan;88(1):40-9. doi: 10.1002/cyto.b.21192. Epub 2014 Oct 20.

11.

Stable Phenotype Of B-Cell Subsets Following Cryopreservation and Thawing of Normal Human Lymphocytes Stored in a Tissue Biobank.

Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, Tramm AM, Baech J, Jacobsen CL, Gaihede M, Kjeldsen MK, Bødker JS, Dybkaer K, Bøgsted M, Johnsen HE.

Cytometry B Clin Cytom. 2014 Sep 20. doi: 10.1002/cytob.21192. [Epub ahead of print]

12.

Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.

Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network.

Exp Hematol. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Epub 2014 Jul 27. Review.

PMID:
25072621
13.

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.

Falgreen S, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Dybkær K, Bøgsted M.

BMC Bioinformatics. 2014 Jun 5;15:168. doi: 10.1186/1471-2105-15-168.

14.

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man.

Bergkvist KS, Nyegaard M, Bøgsted M, Schmitz A, Bødker JS, Rasmussen SM, Perez-Andres M, Falgreen S, Bilgrau AE, Kjeldsen MK, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Dybkær K, Johnsen HE.

BMC Immunol. 2014 Jan 31;15:3. doi: 10.1186/1471-2172-15-3.

15.

Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor.

Rodrigo-Domingo M, Waagepetersen R, Bødker JS, Falgreen S, Kjeldsen MK, Johnsen HE, Dybkær K, Bøgsted M.

Brief Bioinform. 2014 Jul;15(4):519-33.

16.

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells.

Kloster MB, Bilgrau AE, Rodrigo-Domingo M, Bergkvist KS, Schmitz A, Sønderkær M, Bødker JS, Falgreen S, Nyegaard M, Johnsen HE, Nielsen KL, Dybkaer K, Bøgsted M.

BMC Genomics. 2012 Nov 5;13:596. doi: 10.1186/1471-2164-13-596.

17.

Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.

Boegsted M, Holst JM, Fogd K, Falgreen S, Sørensen S, Schmitz A, Bukh A, Johnsen HE, Nyegaard M, Dybkaer K.

PLoS One. 2011 Apr 29;6(4):e19322. doi: 10.1371/journal.pone.0019322.

Supplemental Content

Loading ...
Support Center